Liraglutide belongs to the GLP-1 receptor agonist (GLP-1 RA) drug class. It is structurally derived from native GLP-1(7–36) amide, sharing approximately 97% sequence homology with the endogenous peptide. A C-16 fatty acid chain is attached via a glutamic acid linker to lysine at position 26, enabling reversible binding to plasma albumin and extending the circulating half-life to roughly 13 hours , substantially longer than the native peptide, which is degraded by dipeptidyl peptidase-4 (DPP-4) within minutes of secretion.
In pharmacological terms, liraglutide binds and activates the GLP-1 receptor, a class B G-protein-coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, the cardiovascular system, and the central nervous system. Receptor activation stimulates cyclic AMP production downstream. The endogenous GLP-1 hormone is released from intestinal L-cells in response to nutrient ingestion and plays a role in glucose-dependent insulin secretion, glucagon suppression, and gastric motility , functions that inform why this receptor class is of pharmacological interest.
In Australia, liraglutide is a prescription-only medicine listed on the Australian Register of Therapeutic Goods (ARTG) and regulated under Schedule 4 of the Poisons Standard. Approved indications are determined by the Therapeutic Goods Administration (TGA) and prescribing is subject to the standard requirements for Schedule 4 medicines. Any supply of a GLP-1 receptor agonist peptide outside the approved regulatory pathway , including compounded, imported, or otherwise unapproved forms; is not lawfully permitted for supply in Australia without TGA authorisation; the TGA has issued enforcement guidance on this point.
Liraglutide is distinct from shorter research peptides sometimes marketed outside approved channels. It is not classified under Schedule 9 (Prohibited Substances) of the Poisons Standard; however, unapproved analogues or formulations of GLP-1-class peptides supplied without TGA approval may breach the Therapeutic Goods Act 1989 (Cth), and the TGA has indicated active compliance activity in this area.
Sources: